2022 World Conference on Lung Cancer (ePosters)-EP01.06-005. Assessment of Cardiovascular Risk in the Non Screening Radically Treated Lung Cancer Cohort

EP01.06-005. Assessment of Cardiovascular Risk in the Non Screening Radically Treated Lung Cancer Cohort

Pdf Summary

This study evaluated the cardiovascular risk and statin use in a cohort of patients who had been radically treated for lung cancer. The researchers used the QRISK3 algorithm to calculate the cardiovascular risk score for 66 patients who met the inclusion criteria. The observation period showed that 89.4% of the patients had a QRISK3 score greater than 10%. Among this group, only 23.7% were on statin therapy, while the remaining 76.3% were not taking any statins. The mean QRISK3 for all patients included in the study was 24.4%. The average QRISK3 for those on statin therapy was 29.59%, while for those not on statin therapy, it was 23.9%.<br /><br />Based on these findings, the study suggests that screening for cardiovascular risk in patients undergoing radical lung cancer therapy is effective in identifying those who may benefit from primary prevention. In this case, the majority of patients (76.3%) were identified as candidates for statin therapy due to their significant cardiovascular risk.<br /><br />The researchers recommend addressing cardiovascular risk in post-treatment follow-up clinics for lung cancer patients. They highlight the importance of considering cardiovascular risk assessment as part of the routine care for lung cancer survivors. By identifying high-risk patients, appropriate interventions, such as statin therapy, can be initiated to reduce the risk of cardiovascular morbidity and mortality in this population.

Asset Subtitle

Marius Rohan Theiveehathasan

Meta Tag

Speaker Marius Rohan Theiveehathasan

Topic Early Detection and Screening - Risk Stratification

Keywords

cardiovascular risk

statin use

lung cancer

QRISK3 algorithm

cohort

patients

inclusion criteria

observation period

statin therapy

QRISK3 score